Mylan Recalls Alprazolam Tablets

Article

The company is recalling Alprazolam Tablets, USP C-IV 0.5 mg because of potential presence of foreign substance.

Mylan Pharmaceuticals announced on October 25, 2019 that it was voluntarily recalling one lot of Alprazolam Tablets, USP C-IV 0.5 mg because of potential presence of foreign substance. The recalled lot, number 8082708, was packaged in bottles of 500 and was distributed in the United States between July 2019 and August 2019. Alprazolam Tablets are used to treat anxiety and panic disorder, with or without agoraphobia.

While the company stated in a press release that it had not received any complaints of adverse events related to the recalled lot and that clinical impact from the foreign material would be rare, the risk of infection cannot be ruled out. Adverse events may be reported to FDA through the agency’s MedWatch program.

Source: FDA

 

Recent Videos
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes